Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.2.595

Expression of Nuclear Factor Kappa B (NF-κB) as a Predictor of Poor Pathologic Response to Chemotherapy in Patients with Locally Advanced Breast Cancer  

Prajoko, Yan Wisnu (Department of Surgery, Faculty of Medicine, Diponegoro University)
Aryandono, Teguh (Department of Surgery, Faculty of Medicine, Gadjah Mada University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.2, 2014 , pp. 595-598 More about this Journal
Abstract
Background: NF-${\kappa}B$ inhibits apoptosis through induction of antiapoptotic proteins and suppression of proapoptotic genes. Various chemotherapy agents induce NF-${\kappa}B$ translocation and target gene activation. We conducted the present study to assess the predictive value of NF-${\kappa}B$ regarding pathologic responses after receiving neoadjuvant chemotherapy. Materials and Methods: We enrolled 131 patients with locally advanced invasive ductal breast carcinoma. Immunohistochemistry (IHC) was used to detect NF-${\kappa}B$ expression. Evaluation of pathologic response was elaborated with the Ribero classification. Results: Expression of NF-${\kappa}B$ was significantly associated with poor pathological response (p=0.02). From the multivariate analysis, it was found that the positive expression of NF-${\kappa}B$ yielded RR=1.74 (95%CI 0.77 to 3.94). Conclusions: NF-${\kappa}B$ can be used as a predictor of poor pathological response after neoadjuvant chemotherapy.
Keywords
Locally advanced breast cancer; NF-${\kappa}B$; pathological response; neoadjuvant chemotherapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Von Minckwitz G, Untch M, Blohmer JU, et al (2012). Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol, 30, 1-10.   DOI
2 Schott AF, Hayes DF (2012). Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol, 30, 1747-9.   DOI
3 Smith IC, Heys SD, Hutcheon AW, et al (2002). Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol, 20, 1456-66.   DOI   ScienceOn
4 Voborilova J, Nemcova-Furstova V, Neubauerova J, et al (2011). Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells. Invest New Drugs, 29, 411-23.   DOI
5 Chuthapisith S, Eremin JM, El-Sheemy M, Eremin O (2006). Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon, 4, 211-9.   DOI   ScienceOn
6 Bourgarel-Rey V, Vallee S, Rimet O, et al (2001). Involvement of nuclear factor b in c-myc induction by tubulin polymerization inhibitors. Mol Pharmacol, 59, 1165-70.
7 Chang JC, Hilsenbeck SG (2004). Prognostic and predictive markers. In: Harris JR et al, (eds) Diseases of The Breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, pp.675-96.
8 Chen ZS, Tiwari AK (2011). Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J, 278, 3226-45.   DOI
9 Fan Y, Dutta J, Gupta N, Fan G, Gelinas C (2008). Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol, 615, 223-50.   DOI
10 Ghavami S, Hashemi M, Ande SR, et al (2009). Apoptosis and cancer: mutations within caspase genes. J Med Genet, 46, 497-510.   DOI   ScienceOn
11 Godwin P, Baird AM, Heavey S, Barr MP, Gately K (2013), Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol, 3, 1-10.
12 Gonzalez-Angulo AM, McGuire SE, Buchholz TA, et al (2005). Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol, 23, 7098-104.   DOI
13 IARC (2008). GLOBOCAN 2008, Section of Cancer Information.
14 Jones RL, Rojo F, A'Hern R, et al (2011). Nuclear NF-kappa B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Path, 64, 130-5.   DOI
15 O'Gorman DM, Cotter TG (2011). Molecular signals in antiapoptotic survival pathways. Leukemia, 15, 21-34.
16 Basseres DS, Baldwin AS (2006). Nuclear factor-$\kappa{B}$ and inhibitor of $\kappa{B}$ kinase pathways in oncogenic initiation and progression. Oncogene, 25, 5817-30.
17 Barre B, Coqueret O, Perkins ND (2010). Regulation of activity and function of the p52 NF-$\kappa{B}$ subunit following DNA damage. Cell Cycle, 9, 4795-804.   DOI